Delivery Order SPE2DB22D2007-SPE2DB25FJ4FW
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $4,894.36 to AmerisourceBergen Drug Corp for the supply of Teriparatide 560 mcg/2.24 mL pen injections. The contract, which was awarded on July 30, 2025, with an ultimate completion date of July 31, 2025, represents a firm fixed-price delivery order under a competitive, non-set-aside procurement. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $4,422.77 to AmerisourceBergen Drug Corp for Teriparatide 560 MCG/2.24 ML pen injections on August 18, 2025, with a completion date of August 19, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract represents a child order under the company's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Teriparatide 560mcg/2.24ml pen injections, valued at $22,413.75 under a firm fixed-price contract. The award was made on May 27, 2025, with an ultimate completion date of May 28, 2025, and represents a competitive, non-set-aside procurement. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This delivery order is...
- The Defense Logistics Agency awarded a delivery order valued at $41,615.46 to AmerisourceBergen Drug Corp for the supply of Teriparatide 560mcg/2.24mL pen injections. The contract, issued on September 9, 2025, with an ultimate completion date of September 10, 2025, is structured as a firm fixed-price delivery order with no set-aside designation. Performance will be executed from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order falls under...
- The Defense Logistics Agency awarded a delivery order valued at $5,192.53 to AmerisourceBergen Drug Corp for Teriparatide 560mcg/2.24ml pen injections, with performance in Conshohocken, Pennsylvania and completion by August 27, 2025. This award represents a firm fixed-price delivery order with no set-aside designation, awarded competitively on August 26, 2025. The contract supplies a pharmaceutical product used primarily for osteoporosis treatment, supporting the federal medical supply chain for...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on May 8, 2025, for the supply of Teriparatide 560 mcg/2.24 mL pen injections, with a ceiling value of $5,560.39. This is a firm fixed-price delivery order with an ultimate completion date of May 9, 2025, and represents a non-competitive set-aside award. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 11, 2025, for the supply of Teriparatide 560mcg/2.24ml pen injections with a ceiling value of $5,443.66. This is a firm fixed-price delivery order with no set-aside designation, indicating it was competitively awarded. The contract is scheduled for ultimate completion on August 12, 2025, and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order operates as...
- The Defense Logistics Agency awarded a delivery order valued at $7,313.71 to AmerisourceBergen Drug Corp for the supply of Teriparatide 560mcg/2.24ml pen injections. This competitively awarded, firm fixed price contract with no set-aside designation is scheduled for completion by July 23, 2025, with performance taking place at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The contract represents a routine pharmaceutical procurement to support federal medical supply...
- The Defense Logistics Agency awarded a $26,852.75 delivery order to AmerisourceBergen Drug Corp for the supply of Teriparatide 560 mcg/2.24 mL pen injections. This contract represents a firm fixed-price delivery order with an ultimate completion date of June 3, 2025, and was competitively awarded without set-aside provisions. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Teriparatide is a recombinant human parathyroid hormone used in...
- The Defense Logistics Agency awarded a $3,468.94 delivery order to AmerisourceBergen Drug Corp on July 29, 2025, for the supply of Teriparatide 560mcg/2.24ml pen injections, with a completion date of July 30, 2025. This contract represents a firm fixed-price delivery order with no set-aside designation, indicating competitive award through open competition. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- SPE2DB22D2007Indefinite Delivery Contract
- SPE2DB22D2007-SPE2DB25FJ4FWDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for teriparatide 560 mcg/2.24 mL pen injections, valued at $5,592.67 with a firm fixed price structure. The award, issued on August 22, 2025, with completion targeted for August 25, 2025, represents a non-set-aside competitive award for pharmaceutical supply fulfillment. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is executed under the company's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.99 billion prime vendor agreement running through December 2026 that enables comprehensive pharmaceutical and medical supply distribution to support military healthcare programs globally. AmerisourceBergen Drug Corp is a major pharmaceutical distributor and critical federal vendor providing an extensive portfolio of brand-name and generic medications, vaccines, and medical devices across multiple therapeutic domains to military and veteran healthcare systems. The company's consistent track record of winning competitively awarded delivery orders through the DLA demonstrates its capability to meet federal procurement standards. As a child award under the larger pharmaceutical prime vendor vehicle, this order for teriparatide—a medication used in osteoporosis treatment—reflects the company's role in supplying specialized healthcare commodities essential to military medical operations and the Defense Health Agency's pharmaceutical requirements.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $5.6k | 8/22/25 |